Heightened interferon-alpha/beta response causes myeloid cell dysfunction and promotes T1D pathogenesis in NOD mice.
Increasing attention is drawn to the contributions of abnormalities in both innate and acquired immune responses to the pathogenesis of autoimmune diseases, such as type 1 diabetes (T1D). Dendritic cells (DC) are critical immune cells linking innate and acquired immune responses and previous studies in NOD mice suggest abnormalities in these cells. To address DC dysregulation we examined kinetic global gene expression in NOD and B6 GM-CSF/IL-4-induced bone marrow-derived DC following lipopolysaccharide (LPS)-stimulation. We identified expression differences in over 300 genes including a cluster of 16 interferon (IFN-alpha/beta) target genes overexpressed in NOD DC. Mechanistically, heightened IFN-alpha/beta responses were not due to increased production of this cytokine, IFN-gamma priming or increased Syk kinase activity. We found, however, heightened responses to IFN-alpha/beta in NOD versus B6 as demonstrated by increased type 1 IFN target gene expression, for example, IRF-7, in NOD DC and macrophages. Analysis of multiple congenic strains demonstrated that the Idd5 susceptibility region largely governed heightened IFN-alpha responses. Of interest, heightened IFN-alpha/beta response in NOD mice was not confined to hematopoietic cells but was also seen in the pancreas and beta cells. Compounding the IFN-alpha response defect, NOD mice harbor significantly more PDC in spleen in comparison to B6 and produce four- to sixfold more IFN-alpha when stimulated with CpG. Finally, treatment of NOD mice with IFN-alpha inducing agents, for example, high-dose poly I:C accelerates diabetes in both female and male mice. The abnormalities in the IFN-alpha/beta axis appear to play a significant role in T1D pathogenesis.
Peng
Rui Hua
RH
Department of Pathology, Immunology, Laboratory Medicine, University of Florida, P.O. Box 100275, Gainesville, FL 32610, USA.
Paek
Edward
E
Xia
Chanqing Q
CQ
Tennyson
Nathan
N
Clare-Salzler
Michael J
MJ
D000818:Animals; D003713:Dendritic Cells / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology* / Q000235:genetics / Q000276:immunology* / Q000503:physiopathology; D005260:Female; D005786:Gene Expression Regulation / Q000276:immunology; D007369:Interferon Inducers / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D051379:Mice; D020297:Mice, Congenic; D016688:Mice, Inbred NOD; D022423:Myeloid Cells / Q000187:drug effects* / Q000473:pathology; D011070:Poly I-C / Q000494:pharmacology*
D007369:Interferon Inducers; D008070:Lipopolysaccharides; D011070:Poly I-C